Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.

ABSTRACT:

Importance

Novel oral anticoagulation and antiplatelet therapies have become a mainstay of treatment for thromboembolic disease. However, the safety profile of these medications has not been completely characterized.

Objective

To determine the risk of developing intraocular hemorrhages with novel oral antithrombotic therapy compared with that of traditional antithrombotic agents.

Design, setting, and participants

In this retrospective cohort study, a large national insurance claims database was used to generate 2 parallel analyses. All patients with incident use of dabigatran etexilate or rivaroxaban between January 1, 2010, and September 30, 2015, were compared with patients with incident use of warfarin sodium. Similarly, patients with new use of prasugrel hydrochlo

SUBMITTER: Uyhazi KE 

PROVIDER: S-EPMC5838600 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature